Knight Therapeutics Inc. (TSX:GUD)

Market Cap	632.80M
Revenue (ttm)	384.56M
Net Income (ttm)	383.00K
Shares Out	99.65M
EPS (ttm)	0.00
PE Ratio	1,652.21
Forward PE	226.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,059
Average Volume	61,025
Open	6.47
Previous Close	6.42
Day's Range	6.33 - 6.49
52-Week Range	5.09 - 6.49
Beta	0.16
RSI	59.51
Earnings Date	Aug 7, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD